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Abstract 
Introduction: Sleep plays an important role in memory consolidation. However, the underlying 
mechanism remains elusive. The importance of sleep in the memory consolidation process has 
been demonstrated by sleep deprivation studies in which sleep loss corresponded to poor 
performance on memory tasks. A sleep induction approach, that allows us to study sleep-
mediated changes in the presence of sleep, provides further understanding of sleep’s role in the 
memory consolidation process.   
Method: We first developed a pharmacological method to induce a sleep-like state and 
examined if the induced sleep-like state modulates memory consolidation in flies. Using sleep 
induction, we then evaluated if changes in duration and timing of the induced sleep cause the 
changes in memory outcomes to further understand the role of sleep in the memory consolidation 
process.  
Results: Gaboxadol, an extra-synaptic GABAA receptor agonist, induced a sleep-like state that 
meets all the behavioral criteria of a spontaneous sleep-like state in flies. The induced sleep-like 
state following Gaboxadol treatment facilitated the formation of long-term memory in Wild-type 
flies. Inducing a sleep-like state in different strains of flies (ex. a series of memory mutants) and 
under various experimental conditions (ex. following sleep deprivation) revealed the beneficial 
role of induced sleep in memory processes, as supported by the observations that an increased 
sleep-like state rescued memory deficits in memory mutants and may compensate memory 
impairment caused by sleep-deprivation.  By altering the duration and timing of sleep induction 
following the training protocol that is only able to induce a short-term memory by itself, we 
observed that a short-term memory was consolidated into a long-term memory even at when a 
sleep-like state was induced for a short period of time (<4hrs) or induced at later time (>24hrs) 
following the training.  
Discussion: Incorporating Gaboxadol into food is a novel method to increase a sleep-like state 
that was behaviorally and functionally equivalent to a spontaneous sleep-like state in flies. The 
ability of an induced sleep to sustain the formation of long-term memory following interference 
periods supports the active role of sleep in the memory consolidation process. Future studies 
using sleep induction could complement studies from sleep deprivation and contribute to 
identifying genes and neuronal circuits that link sleep with memory. 
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Introduction 
Sleep plays an important role in memory consolidation (Payne et al., 2009; Saletin et al., 
2011; Stickgold and Walker, 2007; Walker, 2008; Walker et al 2005; Yoo et al., 2007). The link 
between sleep and memory is adjoined by the observation that sleep disruption results in poor 
performance of memory tasks (Graves et al., 2003; Guan et al., 2004). In addition, recent studies 
have also suggested that sleep is implicated in several neurodegenerative disorders (Brown, 
2002; Hayflick et al., 2013; Iranzo, 2013; Ju et al., 2014; Ju et al., 2013; Lehmann et al., 2013; 
Malow, 2004; Sixel-Doring et al., 2014). However, how sleep affects the memory consolidation 
process remains unclear. Additional experimental approaches, such as sleep induction, could aid 
in a better understanding of the molecular mechanism that underlies how sleep affects memory 
consolidation. 
We used the fruit fly Drosophila melanogaster as a model to study the role of sleep in 
memory for a few simple reasons. Its small size, rapid reproduction rates, approximate 15000 
gene number and short life cycle make studies efficient and easily replicated. Its well 
characterized biology and genetic tools such as the GAL4-UAS system allow easy manipulation 
of gene expression in multiple ways (Hendricks et al., 2000).  Moreover, although flies are 
relatively simpler organisms when compared to mammals, the neural circuits that control 
complex biological processes such as sleep and memory are well developed. Flies exhibit a 
sleep-like state (Hendricks et al., 2000a; Hendricks et al., 2000b; Nitz et al., 2002; Shaw et al., 
2000) and are able to form memory (Blum et al., 2009; Tully et al., 1994; van Swinderen, 2009). 
A sleep-like state in flies is also directly correlated with performance in memory task, as sleep 
loss in flies corresponds to poor performance (Seugnet et al., 2009a; Seugnet et al., 2011a; 
Seugnet et al., 2011b; Seugnet et al., 2009b; Seugnet et al., 2009c; Seugnet et al., 2008). Since 
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the ability of flies to recapitulate the effect of sleep on memory and many aspects of sleep appear 
to be controlled genetically, fly does present an useful model for identification of the genes and 
neuronal circuits that link sleep and memory. 
Previously, taking advantage of fly genetics, we developed a method to induce a sleep-
like state in flies (Donlea et al., 2011). This sleep-induction approach allowed us to determine 
changes in memory in the presence of sleep, apart from the sleep-deprivation approach in which 
the function of sleep is proposed based on the negative consequences of losing sleep. 
Beneficially, correlating findings from both the sleep-induction and sleep-deprivation approaches 
could help in the process to determine the function of sleep; the sleep induction approach 
provides additional experimental strategies that would otherwise be difficult with the sleep-
deprivation approach. While the use of genetics to stimulate a group of neurons in the fly’s brain 
is one way to induce a sleep-like state, developing an additional approach which is independent 
of genetics could open the door to a wide range of applications.  
In fact, sleep-inducing drugs have been developed to increase amount of sleep for treating 
sleep abnormalities and disturbances. Although these drugs increase inactive states, whether 
medication-induced inactive states resemble to the spontaneous occurring sleep remains a 
question. Since the levels of endogenous melatonin correlates with sleep-wake cycle, the 
regulatory effect of increased melatonin level on sleep was studied. Although melatonin 
treatment decreased time for falling sleep, melatonin treatment had no effect on maintaining 
sleep (van den Heuvel et al., 2005). In contrast, Gaboxadol, an agonist for the δ-subunit of 
extrasynaptic GABAA receptors, increases slow wave sleep and to maintain sleep in rats and 
human (Dijk et al., 2012; Lancel, 1997; Lundahl et al., 2012; Lundahl et al., 2007). 
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Since the ability of Gaboxadol to increase a sleep-like state in flies remains unknown, in 
the first part of this study, we tested if Gaboxadol induces quiescence in flies and characterized if 
the increased quiescence following treatment had the same properties as spontaneous sleep.  
In the second part of this study, we evaluated the effect of additional sleep-like states on 
memory consolidation in flies. Since the sleep induction method allows temporal control of 
induced sleep, we determined if modification in the duration and timing of additional sleep-like 
states are associated with changes in memory.  
In sum, results from this study provide a new method using drugs to induce a sleep-like 
state in flies. Together with the previously demonstrated genetic method, the pharmacological 
method could validate sleep induction as a method effectively to study the function of sleep. In 
addition, the results from this study have also contributed to a better understanding of the effect 
of additional sleep on memory consolidation. Future studies in sleep induction could 
complement studies from sleep deprivation and contribute to identifying genes and neuronal 
circuits that link sleep with memory.  
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Materials and Methods 
Flies 
Flies were maintained on a diet (yeast, dark corn syrup and agar) at 25°C with approximately 50-
60% humidity under light (8am-8pm): dark (8pm-8am) cycle. Flies used in this study: Canton-S 
(CS) flies were used as Wild-type flies throughout this study, 104y-GAL4, 30y-GAL4, c929-
GAL4, UAS-NachBac, UAS-Lcch3-RNAi, UAS-GRD-RNAi, UAS-RDL-RNAi, UAS-
GABABR1-RNAi, UAS-GABABR2-RNAi, UAS-GABABR3-RNAi, Blistered 
(w*;P{GAL4}bs
1348
), Period ( per01). Flies used in experiment 1.4 (figure 9): rut2080>104y/+, 
rut2080>UAS-NachBac, rut2080;104y-GAL4>UAS-NachBac, dnc1>104y/+, dnc1>UAS-
NachBac, dnc1;104y>UAS-NachBac; dnc1 line was kindly provided by Dr. Bruno Van 
Swinderen. 
Memory mutant flies listed were ordered from Bloomington Fly Center. Dunce (dnc1), Latheo 
(al[1]b[1]lat[6]c[1]sp[1]/SM5), Leonardo (P{ry[+t7.2]=IArB}14-3-3 zeta[P1188]/CyO;ry[506]), 
Lio2 (w[1118];Df(2R)lio[2],pigeon[2]drl[2]), volado (scb[Vol-2]/CyO) 
 
Pharmacology 
Both Gaboxadol (sigma-aldrich CAS#85118-33-8) and SKF97541 were incorporated into fly 
diet (yeast, dark corn syrup and agar) to reach final concentrations of 0.1mg/mL or 0.5mg/mL for 
Gaboxadol and 40μM for SKF. Gaboxadol targets GABAA receptors whereas SKF targets 
GABAB receptors.  
Hydroxyurea (HU) was used to chemically ablate mushroom bodies in fly larvae. Briefly, flies 
were allowed to lay eggs on the freshly prepared apple juice plates. Hatched larvae was picked 
and transferred to either the starvation plate (10% agar in dH2O) with yeast paste with HU (HU 
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group) or the starvation plate with yeast paste only (Vehicle control group) for 4 hours. After 4 
hours of the treatment, larvae were transferred to a vial containing normal food (yeast, dark corn 
syrup and agar).  
 
Measurement of sleep-like state in flies 
Sleep and locomotor activity patterns of flies were measured continuously. Briefly, flies were 
individually placed into a 65mm glass tube that contains food at one end. Each tube containing 
fly was then placed into Drosophila Activity Monitor (TriKinetics). Fly locomotor activity was 
calculated from the number of times a fly crosses the midline of tube. Sleep was defined as a 
period of quiescence that lasts for at least 5 minutes. Total sleep time, average sleep bout 
duration and other sleep parameters were calculated using the Microsoft Excel.  
 
Sleep deprivation and measurement of sleep rebound 
Flies were individually placed into a 65mm glass tube that contains food at one end. Each tube 
was then inserted into a vertical Drosophila Activity Monitor (TriKinetics). The sleep-nullifying 
apparatus (SNAP) was used to sleep-deprive flies without activating stress response. The SNAP 
tilts asymmetrically from -60° to +60° such that each fly is displaced during the downward 
movement 10 times/minute. Following sleep deprivation, flies were allowed to recover. Sleep 
rebound was calculated as % of sleep (min) gained during recovery periods in relative to baseline 
sleep (min) divided by the total sleep (min) lost during sleep deprivation.  
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Measurement of arousal threshold  
Flies were individually placed into a 65mm glass tube containing food. Each tube was inserted 
into a vertical Drosophila Activity Monitor (TriKinetics) to continuously record locomotor 
activity and sleep. The sleep-nullifying apparatus (SNAP) was used to perturb flies.  
Arousal threshold was defined as the number of flies awakened when they were exposed to a 
mechanical perturbation using the SNAP.  
 
Aversive phototaxic suppression (APS) test  
APS test is a learning assay that tests the ability of flies to learn to inhibit their affinity to light in 
the presence of aversive stimulus, as previously described (Le Bourg and Buecher, 2002; 
Seugnet et al., 2009b). Briefly, this assay uses a learning apparatus that contains two transparent 
polystyrene vials vertically positioned at the end of the arms of the T-maze. One vial was lighted 
by a fiber-optic light source (the lighted vial) while the other vial was covered by a gray plastic 
cap such that no light can pass through (the darkened vial). During each learning test, a filter 
paper of the lighted vial was wetted by 320μL of 1M Quinine hydrochloride (the aversive 
stimulus in this assay) whereas that of the darkened vial was kept dry. Each fly was transferred to 
the entrance of the T-maze, allowed to walk through the T-maze and choose between the lighted 
and darkened vial. After each fly made a choice, the fly was removed from the vial and re-
transferred to the entrance of the maze for the subsequent trials. Each fly was tested in 4 blocks 
of 16 trials. To avoid the effect of the right/left bias or the remaining odorous traces in the vial 
choice, the location of lighted vial was altered as RRLLRRLLRRLLRRLL, where R and L 
represent the lighted vial was on the right and left side of the maze, respectively. Time of 
completion for 16 trials and their choice for each trial were recorded. Photopositive (P) was 
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recorded when the fly chose the lighted vial whereas Photonegative (N) was recorded when the 
fly chose the darkened vial.  The leaning score was indicated by the number of photonegative 
choices and calculated for 4 blocks of 4 trials. Microsoft Excel was used to calculate the average 
and standard error of the mean (SEM). A higher learning score indicates good learning.  Flies 
(n>8) were tested for each conditions. Flies chose the darkened vial during the first block (first 4 
trials) were excluded from further experiment since their low light sensitivity may affect the 
choice in this assay.  
 
Courtship conditioning assay  
Courtship conditioning is an associative learning assay in which naïve male flies learn to inhibit 
courtship behaviors by negative experience of rejection (Ganguly-Fitzgerald et al., 2006). This 
assay is consisted of two components: training and memory evaluation. Depending on the 
experimental design, generally, memory was evaluated at 48 hours following the training. 
Briefly, a naïve male fly was exposed to a phenomenally feminized male fly (Tai2) in a 65mm 
glass tube for a period of time (in total of 3 hours). During this “training” period, a naïve male 
attempts to court with unreceptive Tai2 male but receives repeated rejections from Tai2 male. 
Following the training period, a “trained” male fly was separated from the tai2 male and placed 
to a new 65mm glass tube until the memory evaluation. During memory evaluation period, a 
“trained” naïve was again exposed to a new Tai2 male in a 65mm tube for 10 minutes under the 
video recording. The courtship index (CI), the time that the “trained” male spent in courtship 
behaviors during the 10 minutes, was recorded. CI of “trained” male was compared to age and 
genotype matched “naïve” male.  The reduction in CI indicates memory.  
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Modification of training methods in the “training” component of the courtship conditioning assay 
induces different types of memory. 3 hours of consecutive training (a massed training) only 
produces a short-term memory (STM) that cannot be detected at 48 hours following the training. 
In contrast, three 1 hour- training that has 1 hour-rest in-between each training (a spaced 
training) induces a long-term memory (LTM) that can be detected at 48 hours following the 
training.  
Statistics  
We analyzed data using student-t test (two-tailed, unpaired). In all the experiments, P values less 
than 0.05 are considered to be statistically significant.  
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Results 
PART I: Pharmacological method to induce a sleep-like state in flies. 
1.1 Increased quiescence in CS flies following Gaboxadol treatment meets all of the 
behavioral criteria of a spontaneous sleep.  
Because the effect of Gaboxadol on sleep-like state in flies remains unknown, we 
incorporated Gaboxadol (sigma-aldrich CAS#85118-33-8) into the flies food and measured 
changes following treatment. We observed that quiescence in flies was increased in a Gaboxadol 
dose-dependent manner following treatment (Figure 1a). In more detail, the observed increases 
in quiescence were mostly during the day (Figure 1 b) than at night (Figure 1c) following 
Gaboxadol treatment. Since flies sleep most of the night, less change in quiescence at night could 
simply be due to the saturation effect. We also observed a slight increase in the average day and 
night bout duration following Gaboxadol treatment (Figure 1 d and e). Gaboxadol has been 
reported to increase slow wave sleep and maintain sleep in rats and human (Lancel, 1997; 
Lundahl et al., 2007). Since the values for bout duration represent the length of an episode of a 
sleep-like state, our observation that average night bout duration was increased following 
0.1mg/mL Gaboxadol suggests the ability of Gaboxadol to maintain a sleep-like state in flies.  
 14 
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In addition to EEG studies that dissect sleep into different stages, spontaneous sleep can 
also be behaviorally defined (Hendricks et al., 2000a; Hendricks et al., 2000b). Behaviorally, 
sleep is a state during which the quiescence and arousal threshold are increased. Sleep is a 
rapidly reversible state, which distinguishes sleep from coma. Finally, sleep is homeostatically 
regulated, that losing sleep increases the sleep needed to gain back the lost sleep. To address the 
question that increased quiescence in CS flies following Gaboxadol treatment is equivalent to 
spontaneous sleep, we further evaluated arousal threshold, rapid reversibility and homeostatic 
response during increased quiescence following Gaboxadol treatment. To measure the arousal 
threshold, we counted the number of sleeping flies that woke up by a mechanical disturbance. 
We found similar levels of increased arousal threshold in flies during spontaneous sleep as 
during the increased quiescence following 0.1mg/mL Gaboxadol treatment (Figure 2). Also, a 
further increase in arousal threshold was observed during the increased quiescence following 
0.5mg/mL Gaboxadol (Figure 2). 
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The observation that flies respond to a mechanical disturbance during increased quiescence 
following Gaboxadol treatment indicates that increased quiescence was rapidly reversible. To 
determine if losing the increased quiescence mediates a homeostatic response, we sleep deprived 
flies during Gaboxadol treatment and measured the presence of sleep rebound following sleep 
deprivation. We found that when spontaneous sleep (Figure 3a) or increased quiescence (Figure 
3b) following Gaboxadol in flies was lost by overnight sleep deprivation, flies exhibited an 
increased sleep-like state following the sleep deprivation (Figure 3c and d).  
 
 
 
Collectively, our results indicate that while quiescence and arousal threshold was 
increased during the increased quiescence following Gaboxadol treatment, the increased 
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quiescence was rapidly reversible. The increased quiescence following 0.1mg/mL Gaboxadol 
was regulated by homeostasis, as evidenced by the observation that flies exhibited sleep rebound 
to recover a decrease in quiescence. Therefore, the increased quiescence following Gaboxadol 
met all the behavioral criteria of spontaneous sleep.  
1.2 Knockdown the expression of GABA receptors in the Mushroom Bodies and Clock cells 
alters the response in flies following Gaboxadol treatment.  
Gaboxadol targets δ-units of extra-synaptic GABAA receptors in mammals (Lancel, 
1999; Winsky-Sommerer et al., 2007) . To determine if the increased quiescence following 
Gaboxadol treatment is mediated through the activation of GABA receptors in flies 
(Buckingham et al., 2005; Hosie et al., 1997), we used RNAi to knockdown the expression of six 
GABA receptors; Lcch3, GRD, Rdl, GABABR1, GABABR2 and GABABR3, in the Mushroom 
bodies (MB: 30y-) and Clock cells (c929) and evaluated the response in flies following 
Gaboxadol treatment. We observed that knocking down the expression of Lcch3, GRD or 
GABABR1 subunits in the MB (Figure 4 a) and clock cells (Figure 4 c) significantly reduced the 
amount of increased quiescence following 0.1mg/mL Gaboxadol treatment. In addition, because 
a GABAB agonist, SKF also increases quiescence in flies, we also evaluated the effect of the 
GABA receptor knockdown on the response following SKF treatment. We observed that the 
increased quiescence following SKF treatment was reduced if the expression of GABAB 
receptors (R1, R2 and R3) were abolished in the MB (Figure 4 b). Knocking down expressions 
of any six GABA receptors (Lcch3, GRD, Rdl, GABABR1, GABABR2 or GABABR3), in clock 
cells had no effect on the response following SKF treatment (Figure 4d).  
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In sum, our results suggest that the expressions of three GABA receptors; Lcch3, GRD, 
and GABABR1, in the MB and clock cells are required to mediate the increased quiescence 
following Gaboxadol treatment.  
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1.3. Increased quiescence following Gaboxadol treatment facilitates a long-term memory 
formation.  
Flies form a long-term memory when sleep-like state was increased by genetic method 
following a massed training protocol of Courtship conditioning that itself does not induce LTM 
(Donlea et al., 2011). To determine if the increased quiescence following Gaboxadol treatment 
facilitates a long-term memory formation, quiescence was increased for 4 hours by 0.1mg/mL 
Gaboxadol treatment immediately following the massed training protocol and memories were 
evaluated. No long-term memory was observed in flies following a massed training in the 
absence of increased quiescence (Figure 5a). In contrast, a long-term memory was observed in 
flies that had increased quiescence by Gaboxadol treatment following a massed training (Figure 
5b).  
 
 
Like spontaneous sleep, our observations suggest that increased quiescence by Gaboxadol 
treatment has the ability to facilitate long-term memory formation.     
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1.4 Increased quiescence following Gaboxadol treatment does not enhance a short-term 
memory in CS flies, but improves a short-term memory in learning mutants.  
A short-term memory (STM) in flies can be evaluated using an APS test (Seugnet et al., 
2009b). Although CS flies learn normally in the APS test, we asked if additional quiescence 
following Gaboxadol could make CS flies even better learners. The quiescence was increased in 
CS flies for 2 days by Gaboxadol treatment prior to the APS test and learning was evaluated. 
Increased quiescence following Gaboxadol in CS flies had no effect on their learning, as 
evidenced by the observation that the performance of Gaboxadol-fed flies in the APS test was 
similar to that of their age-matched non-drug-fed controls (Figure 6). While quiescence was 
increased in CS flies following Gaboxadol treatment, the observation that the increased 
quiescence did not enhance learning prompts us to hypothesize that the beneficial effect of the 
increased quiescence on STM may be demands-specific.   
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A series of memory mutant flies were identified previously using a classic olfactory 
learning paradigm (Boynton and Tully, 1992; Dura et al., 2007; Grotewiel et al., 1998; Mery et 
al., 2007; Philip et al., 2001; Pinto et al., 1999; Qiu and Davis, 1993; Skoulakis and Davis, 1996; 
Tully and Quinn, 1985). Among these mutants, we found nine mutant flies; rut2080, dunce, pst-1, 
latheo, Leonardo, volado, lio, forS2 and dumb2, that also present learning impairment in the APS 
test. We measured quiescence in these mutants following Gaboxadol treatment. As in CS flies 
(Figure 7a), quiescence was increased in each mutant following Gaboxadol treatment (Figure 7b-
j).  
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Except in dumb2 flies, the increased quiescence improved short-term memory in all the mutants 
(rut2080, dunce, pst-1, latheo, Leonardo, volado, lio2) (Figure 8a and c-h). The beneficial effect 
on short-term memory was mediated by increased quiescence, as supported by the observation 
that no improvement in short-term memory was observed if flies were sleep-deprived during 
Gaboxadol treatment (Figure 8a and c-h).  
To further verify that the improvement of STM deficits is sleep-like state dependent, 
sleep-like state was increased by genetic method (Donlea et al., 2011) using 104y>NachBac and 
associated changes in memory were evaluated. We observed that STM deficits in rut2080 and 
dunce were also reversed using 104y>NachBac (Figure 9a-b).  
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1.5 Increased quiescence following Gaboxadol treatment may improve short-term memory 
formation in Hydroxyurea (HU) treated CS flies. 
Since lio2 flies present structural abnormality (Moreau-Fauvarque et al., 1998) and 
Gaboxadol induced a sleep-like state that improved their learning, we further evaluated the effect 
of increased quiescence on memory deficits caused by structural abnormality. Mushroom Bodies 
(MB) is a critical structure in the flies brain (Strausfeld et al., 1998) that regulates both sleep 
(Guo et al., 2011) and learning and memory (Akalal et al., 2006; Blum et al., 2009). Treatment 
with Hydroxyurea (HU) in larvae chemically ablates MB; therefore HU-treated flies have a 
reduced sleep-like state and are impaired in short-term memory formation (de Belle and 
Heisenberg, 1994). Based on the role of MB in a sleep-like state and memory, we first 
determined if the quiescence is increased in HU-treated CS flies following Gaboxadol treatment 
and then evaluated short-term memory. Quiescence was increased by Gaboxadol treatment (data 
not shown). While the increased quiescence improved short-term memory deficit in HU-treated 
flies (Figure 10a), the increased quiescence did not improve long-term memory (Figure 10b-c).  
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1.6 Increased quiescence following Gaboxadol improves long-term memory deficits in 
period (per
01
) and blistered (bs
1348
) flies.  
  Since long-term memory formation following a spaced training is impaired in per
01
 and 
bs
1348
 flies, we determined if increased quiescence following Gaboxadol treatment can rescue 
LTM deficits in these flies.  Quiescence in per
01
 and bs
1348
 flies were increased for 2 days by 
Gaboxadol treatment prior to the spaced training, flies were removed from Gaboxadol food 
during the training, and flies were placed back onto Gaboxadol food for 24 hours following the 
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training.  We observed that increased quiescence in per
01
 and bs
1348
 flies following Gaboxadol 
treatment improved long-term memory deficits (Figure 11c-d and f-g). 
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PART II: Study the role of sleep in memory consolidation using sleep-induction.  
Since sleep is required to consolidate short-term memory, produced by massed training, 
to a long-term memory that can be observed at 48 hours following the training, changing the 
duration and timing of the induced sleep could further dissect the temporal relationship between 
induced sleep and long-term memory formation. First, to address the question on how much 
sleep is required to facilitate long-term memory formation, we determined the ability of a short 
duration of induced sleep (<4hr) to consolidate memory (Result 2.1). Next, we evaluated if 
modification in the timing of sleep induction is associated with changes in memory (Result 2.2). 
Lastly, to challenge the hypothesis that sleep only passively protects memory from degradation 
by simply acting as a shelter, we tested the ability of induced sleep to compensate sleep-
deprivation-mediated memory interference (Result 2.3).   
2.1: a short duration of an induced sleep-like state (<4hr) following learning is sufficient to 
facilitate memory consolidation.  
To address the effect of sleep duration on memory consolidation, we induced a short-
duration (<4hr) of sleep using a genetic method (Donlea et al., 2011) in flies immediately 
following the massed training protocol and then evaluated the memories at 48 hours after 
training. Flies that slept for either 1 hour or 2 hours immediately following the massed training 
were able to form a long-term memory (Figure 12 a-b), whereas flies that were only massed 
trained without sleep exhibited no memory (data not shown). To further determine if the 
beneficial effect on memory consolidation was sleep-dependent, we sleep-deprived flies while 
the circuit was activated. We found that activation of the circuit alone produced no memory 
(Figure 12c). Collectively, these data indicate that a short duration (<4hrs) of induced sleep was 
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sufficient to consolidate memory. Importantly, sleep, rather than the activation of Fan-shaped 
body alone, mediates the beneficial effect on memory consolidation.  
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2.2 Sleep that is induced 24 hours after the training also facilitates memory consolidation.  
In addition to determining the effect of sleep duration on memory consolidation, we also 
examined the effect of sleep timing on memory consolidation. 4 hours of sleep were induced in 
flies at 24 hours following massed training and memories were evaluated. We found that flies 
that slept for 4 hours post massed training presented a long-term memory (Figure 13a). Notably, 
we observed that 2 hours of sleep at 24 hour after the massed training also facilitated long-term 
memory formation (Figure 13b). Collectively, these results suggest the ability of induced sleep to 
facilitate memory consolidation even when it is introduced at a later time.  
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2.3 Sleep plays an “active” role in memory consolidation: 4 hours of induced sleep 
compensates the memory interference caused by sleep deprivation. 
A memory system contains three consecutive stages: encoding, consolidation and 
retrieval. During encoding stage, information through sensory inputs is converted to a memory 
trace which is susceptible to incoming interference. The newly formed memory trace is stabilized 
during the consolidation process and is being stored until the retrieval stage at when the stored 
memory is recalled. Despite the involvement of sleep in the memory consolidation process, 
sleep’s role in memory consolidation remains the center of debate. Two hypotheses (Ellenbogen 
et al., 2006a; Ellenbogen et al., 2006b)have been proposed for how sleep is involved in memory 
consolidation. The “passive” hypothesis posits that sleep passively protects memory from 
degradation by serving as a temporal shelter from any negative effect of ongoing cognitive 
activity. In contrast, the “active” hypothesis argues that sleep can either directly or indirectly 
trigger the memory consolidation process in addition to supplying the reduced interference 
period.  
Whether sleep facilitates memory consolidation by only supplying the reduced 
interference period remains to be defined. Our observation that induced sleep at later time also 
facilitates memory consolidation (section 2.2) supports the notion that sleep may have an “active” 
role in memory consolidation, rather than sleep only acts as a shelter of interference. To address 
this question, we determined the effect of induced sleep on a long-term memory formation 
following the interference period caused by sleep-deprivation. It is quite established idea that 
sleep deprivation has a negative impact in memory consolidation. A work in flies also 
demonstrated that sleep deprivation after the training abolishes the ability to form a long-term 
memory (Ganguly-Fitzgerald et al., 2006). Flies did not form a long-term memory when sleep-
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like state was increased for 4 hours following 4hours of sleep deprivation (Figure 14a). 
Increasing sleep-like state for 4 hours following 2 hours of sleep deprivation may permit the 
expression of LTM (Figure 14b).  
Together, these results suggest that memory consolidation during sleep is more likely an 
active process rather than a passive state in which sleep only provides a time of reduced 
interference. 
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Discussion 
We observed that quiescence in flies was increased by Gaboxadol treatment. The increase 
in quiescence was mediated by the action of Gaboxadol through GABA receptors in flies. The 
increased quiescence following Gaboxadol treatment met all the behavioral criteria of a 
spontaneous sleep-like state in flies. The function of increased quiescence in memory was 
evidenced by the observation that LTM was formed in flies when the quiescence was increased 
by Gaboxadol treatment following a massed training that itself does not induce LTM. Together, 
our observations suggest that the increased quiescence observed in flies following Gaboxadol 
treatment is behaviorally and functionally equivalent to the spontaneous sleep-like state. 
Therefore, Gaboxadol can be used to induce a sleep-like state in flies.  Sleep induction using 
drugs does not require genetic crosses; thereby it is more technically convenient and allows 
further application such as high-throughput screening. 
Although drug treatments often cause anesthesia, our observations suggest that increased 
quiescence following Gaboxadol treatment is a sleep-like state rather than an amnestic effect of 
Gaboxadol. First, the increased quiescence was rapidly reversible as evidenced by the 
observation that the ability of flies to respond to a mechanical SNAP was not altered by the 
Gaboxadol treatment. External stimulus mediated rapid transition between a sleep and wake state 
which is a distinguished feature found only in sleep not in coma state. Second, the increased 
quiescence was regulated by homeostasis. Third, the ability of increased quiescence to facilitate 
memory formation is sleep-dependent, as evidenced by the observation that memory formation 
was disrupted when flies were sleep-deprived while they were on Gaboxadol. The ability of 
anesthesia to enhance memory consolidation has not been reported.   
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The hypothesis that additional sleep-like state following Gaboxadol treatment mediates 
beneficial effect on memory formation was further supported by our observation that increased 
sleep-like state following sleep induction using genetics also facilitated memory formation. 
Therefore, using both methods of sleep induction, we demonstrated the ability of sleep-like state 
to facilitate memory formation in flies.  
Furthermore, our observations that increased quiescence in flies following Gaboxadol 
treatment rescued STM and LTM deficits in memory mutants suggest the therapeutic role of 
additional sleep in memory deficit. In flies, most memory formation, if not for all, requires the 
Mushroom bodies (MB), a structure in flies brain that is analogous to the hippocampus in 
mammals (Davis, 1993). The excitatory cAMP/PKA signaling in MB is critical for learning and 
memory and gene mutations that alter the cellular cAMP level lead to memory impairment as 
observed in rut2080 and dunce flies (Davis et al., 1995). In addition, MB is also innervated by 
GABAergic neurons (Yasuyama et al., 2002) and inhibitory GABAergic signaling is as 
important as cAMP signaling in learning and memory (Busto et al., 2010; Liu and Davis, 2009). 
The proper interaction and balance between the two signals may be important for memory 
formation, as that alternation in cAMP signaling-mediated suppression of GABAergic inhibition 
could underline the cognitive impairments in memory mutants. Because cAMP-PKA pathway in 
MB also is implicated in sleep (Chen et al., 2013; Hendricks et al., 2001; Joiner et al., 2006), it is 
possible that changes in sleep may modulate cAMP-PKA pathway. Therefore, reversal of STM 
deficits in rut2080 and dunce flies could be mediated by the ability of increased sleep-like state 
following Gaboxadol or genetic treatment to compensate the reduction in cAMP-mediated 
suppression of GABAergic inhibition.  
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Memory in flies is also affected by genes that are not in the cAMP/PKA pathway, as flies 
with mutations in these genes also present memory impairment (Kahsai and Zars, 2011). 
Importantly, sleep-like state in flies is also regulated by various genes, pathways and brain 
regions (Bushey and Cirelli, 2011; Ishimoto et al., 2012). Our observation that increased sleep-
like state reversed STM deficits in pst-1, latheo, Leonardo, volado, lio2 flies supports the ability 
of sleep to induce global effect on memory, as a result of sleep-mediated changes in expression 
level of genes and protein, and the changes in excitability within and the connection between 
neuronal circuits that are implicated in memory. Therefore, further studies that identify the 
changes in gene transcription level and excitability of neuronal circuit that are associated with 
modification of sleep would further dissect the connection between sleep and memory.  
In addition, dopamine neurons are involved in the presentation of aversive information to 
the MB during olfactory learning (Mao and Davis, 2009). Our observation that STM deficit in 
dumb2 mutant was not reversed by the increased sleep-like state supports this function of 
dopamine neurons. The function of dDA1 receptor is abolished due to the gene mutation in 
dumb2 mutant, STM deficit could not be reversed simply because there is no learning to begin 
with.  
Moreover, our observation additional sleep rescues the STM deficit in MB ablated flies 
was intriguing, given the role of MB in learning and memory (Davis, 1993; Keene and Waddell, 
2007; Zars, 2000). This observation may suggest that additional sleep can bypass MB and permit 
the expression of memory by the activation of other process, such as transcriptional regulation of 
genes that are involved in memory. However, our results could be misleading by the incomplete 
ablation of MB following hydroxyl-urea treatment. MB contains approximately 5000 Kenyon 
cells (2500 per hemisphere) that are divided into three lobes: α/β, α’/β’ and ϒ (Crittenden et al., 
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1998).  Each lobe is implicated in different process of memory (Blum et al., 2009; Davis, 2011; 
Krashes et al., 2007; McGuire et al., 2001). Further studies that examine the correlation between 
degree of MB ablation and memory performance in individual fly could address the role of sleep 
in memory in the absence of MB.  
Because the sleep induction method allows for a temporal control of additional sleep, we 
evaluated if modifications to the duration and timing of additional sleep was associated with 
changes in memory. 4 hours of increased spontaneous sleep seems to be required for a long-term 
memory formation following a spaced training (Ganguly-Fitzgerald et al., 2006). Our 
observation that even a short duration (<4 hour) of additional sleep facilitated memory suggest 
the hypothesis that induced sleep may be better than spontaneous sleep. Studies that compare the 
length that memory can last following induced sleep and spontaneous sleep is one approach to 
test this hypothesis. Results from further studies could address the effect of sleep quality on 
memory consolidation.  
Finally, whether sleep passively or actively affects the memory consolidation process 
remains to be the center of debate. We observed that additional sleep following an interference 
period, either it occurred naturally or artificially by sleep deprivation, had ability to consolidate 
memory. Therefore, our results support the active roles of sleep in memory consolidation. In line 
with our observations, the active roles of sleep are also demonstrated in other biological 
processes. Sleep regulates brain mechanism in metabolites clearance (Xie et al., 2013) and also 
regulates transcription of genes including those involved in metabolism (Moller-Levet et al., 
2013).   
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Abstract 
Introduction: Accumulation of aggregated alpha-synuclein protein is the defining pathologic 
feature of Parkinson’s disease (PD). However, the molecular mechanisms underlying protein 
aggregation remain to be defined. Because the physiological function of alpha-synuclein remains 
unclear and previous studies have indicated a role in fatty acid metabolism and specifically acyl 
CoA synthesis, further studies that examine the interaction of alpha-synuclein with free fatty 
acids could provide a better understanding of the protein’s normal function.  
Method: We examined the interaction of alpha-synuclein with oleic acid, a monounsaturated 
free fatty acid, using a scintillation proximity assay (SPA). We characterized the regions of 
alpha-synuclein protein that are required for oleic acid binding using mutagenesis studies. We 
over-expressed alpha-synuclein in HEK293FT cells and measured its effect on the rate at which 
oleic acid is incorporated into phospholipids, which is determined by the rate at which oleic acid 
is converted to oleyl CoA by acyl CoA synthetase enzymes.  
Results: We found that alpha-synuclein cooperatively binds to monomeric oleic acid. Mutations 
that change either amino acids 30 or 46 in the alpha-synuclein protein disrupt the alpha-
synuclein-oleic acid interaction. Over-expression of WT alpha-synuclein, but not A30P alpha-
synuclein, in HEK293FT cells increased the rate of oleic acid incorporation into 
phosphatidylcholine (PC). 
Discussion: SPA is a novel approach to characterize the binding of alpha-synuclein to oleic acids. 
Alpha-synuclein promotes an increase in the oleic acid incorporation rate in HEK293FT cells. 
The absence of oleic acid binding by A30P alpha-synuclein and the corresponding absence of an 
effect of A30P alpha-synuclein on the incorporation rate in cells further supports the hypothesis 
that alpha-synuclein promotes acyl CoA synthesis by binding to free fatty acids.    
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Introduction 
The defining pathologic change in Parkinson disease (PD) is the accumulation of aggregated 
alpha-synuclein protein in Lewy bodies and neurites. Alpha-synuclein is a soluble 140-amino-
acid protein expressed throughout the central nervous system with predominant localization to 
the presynaptic terminals of neurons (Iwai et al., 1995; Maroteaux et al., 1988). The structure of 
the protein contains three distinct domains: the N-terminus domain, the internal hydrophobic 
NAC domain and the C-terminus domain. The N-terminus (residues 1-60) contains seven 
imperfect repeats (KTKEGV) that form alpha-helical secondary structure upon interaction with 
phospholipid vesicles and micelles in vitro (Bisaglia et al., 2005; Chandra et al., 2003; Davidson 
et al., 1998; Ulmer et al., 2005) The internal hydrophobic NAC domain (residues 61-95) 
participates in self-aggregation of the protein to form fibrils that are rich in β-sheet secondary 
structure (Ueda et al., 1993). The C-terminus (residues 96-140) provides structural flexibility to 
the protein.  
While alpha-synuclein gene mutations, including gene multiplication and point mutations, 
cause rare familial forms of PD (Chartier-Harlin et al., 2004; Ikeuchi et al., 2008; Kiely et al., 
2013; Kruger et al., 1998; Polymeropoulos et al., 1997; Proukakis et al., 2013; Singleton et al., 
2003; Zarranz et al., 2004), most cases of PD are sporadic and related to a combination of 
genetic and environmental risk factors. The self-aggregation of alpha-synuclein to form fibrils is 
observed in all PD cases and several other neurodegenerative disorders (REF). The molecular 
mechanisms underlying protein aggregation remain to be defined. It is possible that alteration in 
normal function of the protein could change protein structure to the conformational state that is 
prone to aggregate. Because the physiological function of the alpha-synuclein protein remains 
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elusive, further studies that identify the normal function of the protein could also aid the 
understanding on the self-aggregation property of the protein.    
Among many proposed normal functions of alpha-synuclein, the interaction of alpha-
synuclein with fatty acids has been observed in both in vitro (Assayag et al., 2007; Broersen et 
al., 2006; De Franceschi et al., 2009; Karube et al., 2008; Lucke et al., 2006; Perrin et al., 2001; 
Sharon et al., 2003; Sharon et al., 2001; Varkey et al., 2013) and in vivo studies (Golovko et al., 
2005; Golovko et al., 2006; Golovko et al., 2007). Alpha-synuclein hinders the formation of fatty 
acid micelles in vitro (Broersen et al., 2006; De Franceschi et al., 2009). In vivo studies of alpha-
synuclein-KO mice revealed that fatty acid metabolism, specifically the incorporation rate of free 
fatty acids into brain lipids, is altered in the absence of the alpha-synuclein gene (Golovko et al., 
2005; Golovko et al., 2007). Furthermore, a recent population-based study reported that 
increased dietary intake of fatty acids lowers the risk of developing PD (de Lau et al., 2005). 
Together these studies suggest that the regulation of fatty acid metabolism could be a normal 
function of alpha-synuclein protein. Importantly, the notion that alpha-synuclein regulates fatty 
acid metabolism could explain our recent observation that alpha-synuclein overexpression 
improves motor deficit of pla2g6-KO mice, an animal model of Infantile neuroaxonal dystrophy 
(INAD).   
Infantile neuroaxonal dystrophy (INAD) is a fatal progressive neurodegenerative disorder 
for which there is currently no treatment. Onset of INAD typically occurs in early childhood and 
INAD patients display progressive motor, sensory and cognitive impairment (Farina et al., 1999; 
Nardocci et al., 1999). The defining histopathologic changes in INAD include the accumulation 
of alpha-synuclein in Lewy bodies and neurites, and the presence of neuroaxonal spheroids 
containing tubulovesicular membranes in axons and dendrites throughout the nervous system 
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(Newell et al., 1999; Riku et al., 2013; Simonati et al., 1999; Wakabayashi et al., 2000). Notably, 
mutations in the PLA2G6 gene (chromosome 22q12-q13) which encodes Ca2+ independent 
phospholipase A2β (iPLA2β) are identified in most INAD patients (Gregory et al., 2008; Morgan 
et al., 2006). This enzyme was originally identified in the Chinese hamster ovary (CHO) cell line 
based on its ability to hydrolyze sn-2 ester bond of phospholipids to release free fatty acids and 
lysophospholipids (Wolf and Gross, 1996). 
 
The molecular mechanisms underlying neurodegeneration in INAD remain to be defined. 
Because pla2g6 mutations abolish the ability of the enzyme to produce free fatty acids from the 
hydrolysis of phospholipids (Engel et al., 2010), and because fatty acids are involved in many 
metabolic processes, the deficiency in fatty acid production caused by Pla2g6 mutations may be 
central to the pathogenesis of INAD.  To better understand the mechanism by which Pla2g6 
dysfunction causes neurodegeneration, Pla2g6-KO mice were generated by Neo gene insertion at 
exon 9 (Bao et al., 2004). Pla2g6-KO mice replicate both behavioral and histopathological 
features of human INAD including progressive motor impairment and neuroaxonal spheroid 
formation throughout the nervous system (Malik et al., 2008). Compared to WT mice, Pla2g6-
KO mice present an age-dependent impairment in rotarod test (Malik et al., 2008). To further 
investigate the role of alpha-synuclein protein aggregation observed in INAD, human WT alpha-
synuclein was overexpressed in Pla2g6-KO mice. Interestingly, overexpression of human-WT-
alpha-synuclein significantly improved motor deficits in Pla2g6-KO mice (unpublished data).   
Fatty acid metabolism is essential to many downstream metabolic processes, including 
storage of energy in the form of triglycerides, production of energy through beta-oxidation, new 
lipid synthesis and remodeling and signaling (Black et al., 2000; Grintal et al., 2009; Miller et al., 
1987; Rapoport, 2001; Tol, 1975). The sources of the free fatty acids come from both outside 
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and inside of the cells. Free fatty acids from dietary intake enter cells either by passive diffusion 
through the cell membrane or via flip-flop mechanism, which may be aided by FABP mediated 
transport (Hamilton and Brunaldi, 2007). Inside cells, free fatty acids are generated by a variety 
of lipase enzymes that release free fatty acids from phospholipids and other lipid classes. Finally, 
free fatty acids, or specifically acyl CoAs are produced by fatty acid synthase through the de 
novo fatty acid synthesis pathway that includes desaturation and elongation reactions. In order to 
be utilized in downstream metabolic processes, almost all free fatty acids must be activated by 
acyl CoA synthetase (ACS) enzymes to form Acyl-CoAs (Soupene and Kuypers, 2008). Pla2g6 
mutations that impair catalytic activity may alter fatty acid metabolism by reducing the free fatty 
acid pools that are available for activation. Therefore, approaches that increase the efficiency of 
fatty acid activation could correct the altered fatty acid metabolism by compensating for 
impaired free fatty acid production.  
Based on the previous observation that fatty acid incorporation rates were reduced in the 
absence of alpha-synuclein gene (Golovko et al., 2005; Golovko et al., 2007), and our 
observation that human WT-alpha-synuclein increases the catalytic rate of ACS enzymes in vitro 
(unpublished), we hypothesized that the protective effect of alpha-synuclein in Pla2g6-KO mice 
is mediated by increased conversion of fatty acids to fatty-acyl-CoAs, which compensates for 
impaired fatty acid production caused by Pla2g6 mutations. Further studies that examine the 
alpha-synuclein-fatty acid interaction could begin to address this hypothesis.    
Since previous studies examining a direct interaction between alpha-synuclein and fatty 
acids have generated inconsistent results (Golovko et al., 2005; Karube et al., 2008; Sharon et al., 
2001), in the first part of our study, we characterized the binding of alpha-synuclein to free fatty 
acids using a scintillation proximity assay (SPA). Because the N-terminus of the protein has been 
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reported to mediate binding to phospholipid vesicles and micelles (Chandra et al., 2003; 
Davidson et al., 1998; de Laureto et al., 2006; Eliezer et al., 2001; Ulmer et al., 2005; Varkey et 
al., 2013) and because the N-terminus of the protein hosts the identified point mutants that are 
associated with familial PD (Kiely et al., 2013; Kruger et al., 1998; Polymeropoulos et al., 1997; 
Proukakis et al., 2013; Zarranz et al., 2004), in the second part of our study, we characterized the 
regions of alpha-synuclein protein that are required for oleic acid binding using mutagenesis 
studies. Lastly, to determine if alpha-synuclein overexpression promotes fatty acid metabolism in 
cell culture, we measured the effect of alpha-synuclein overexpression on the fatty acid 
incorporation rate in HEK293FT cells.  
Together, findings from this study will provide a better understanding about the direct 
interaction of alpha-synuclein with free fatty acids, and the effect of alpha-synuclein-fatty acid 
interaction on fatty acid metabolism. Given that fatty acids are involved in many metabolic 
processes, and that the normal function of alpha-synuclein is unknown, findings on the alpha-
synuclein-fatty acid interaction could ultimately contribute to a better understanding of the 
physiological function of the protein.  
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Materials and Methods 
Recombinant protein expression and purification 
To produce each recombinant alpha-synuclein protein, BL21 (DE3) competent cell was 
transformed with pRK172 plasmids containing human WT or mutant alpha-synuclein. Control 
protein was generated from BL21 cells transformed with an empty expression plasmid as 
described (Bagchi et al., 2013). The colony containing each construct of plasmid DNA was 
picked and inoculated in TB media at 37°C for 16 hours prior to purification. The cells were 
harvested by centrifugation at 3900 xg for 10 minutes at 25°C. The supernatant was discarded. 
To lyse the cells, the pellet (cells) was resuspended in 20mL of osmotic shock buffer (30mM 
Tris-HCl, 2mM EDTA, 40% sucrose pH7.2), incubated in the buffer at room temperature for 10 
minutes and collected by centrifugation at 8000 xg for 10 minutes at 25°C. The outer cell 
membrane was removed by resuspention and incubation (3 minutes on ice) of the pellet in ice-
cold MQ water and 2M MgCl2, followed by centrifugation at 20,000xg for 15 minutes at 4°C. 
The supernatant (periplasmic) was collected and DNA was precipitated by addition of 
streptomycin mixture and centrifugation at 20,000xg for 15 minutes at 4°C. The supernatant was 
heated at 95°C water bath for 10 minutes to further separate alpha-synuclein protein from other 
proteins. To further increase the purity of alpha-synuclein, the supernatant was filtered with 
0.45µm filter and loaded onto a chromatography column (Bio-Rad Laboratories) containing 1mL 
of DEAE sepharose beads (Sigma) in 20mM Tris-HCl and 1mM EDTA. Each column was 
washed with 10mL of ice-cold wash buffer (20mM Tris-HCl pH8, 1mM EDTA and 1mM DTT) 
and each alpha-synuclein protein was eluted with 0.3M NaCl elution buffer (20mM Tris-HCl 
pH8, 1mM EDTA, 1mM DTT and 0.3M NaCl). The elutant was dialyzed overnight in 5L of 
dialysis buffer. The protein concentration of each construct was measured using BCA assay.  
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Mutagenesis  
Forward and reverse primers for each construct were designed using online program (Agilent 
technologies) and ordered from integrated DNA technologies. Using the QuikChange site-
directed mutagenesis (Agilent technology Inc), each alpha-synuclein mutant was created by a 
single amino acid mutation onto the His-tagged WT alpha-synuclein-pRK172 plasmid (Table 1).  
 Nucleotide 
location 
Amino acid 
substitution 
WT-alpha-syn pRK172   
A30P-alpha-syn pRK172 88 G to C 
E46K-alpha-syn pRK172 188 G to A 
H50Q-alpha-syn pRK172 150 T to G 
G51D-alpha-syn pRK172 152 G to A 
A53T-alpha-syn pRK172 209 G to A 
Each plasmid was transformed into DH5α competent cells for DNA expression. Plasmid DNAs 
from the competent cells were purified using the QIAprep®Spin Miniprep Kit following the 
manufacture’s protocol (Qiagen). The concentrations of purified plasmid DNA were determined 
by measuring absorption at 260 nm using NanoDrop spectrophotometer. Nucleotide sequences of 
all plasmids were confirmed by DNA sequencing.     
Scintillation Proximity Assay (SPA)-binding assay 
The binding interaction of alpha-synuclein with oleic acid was examined using Scintillation 
Proximity Assay. Chelated copper PVT SPA beads (PerkinElmer) and purified his-tagged empty 
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vector/alpha-synuclein proteins were diluted in 30mM Tris-HCl pH7.4 buffer such that the final 
concentrations of SPA bead and protein were 0.2mg/mL and 4µg/mL, respectively. 
3
H-labeled 
oleic acid (American radiolabeled chmicals Inc) was mixed with unlabeled oleic acid at a ratio of 
1:100. Oleic acid was first diluted in DMSO to 100x of each final concentration, and then diluted 
in 30mM Tris-HCl pH7.4 buffer to the final concentration of 0.5, 2, 3.5, 5, 6.5, 7 and 8µM. To 
reduce the non-specific binding of protein to the plastic plate, each well of the 96-well 
microplate was coated with 200µL of 0.02% gelatin (Sigma) and incubated at 37°C for 30 
minutes prior to each experiment. 0.02% gelatin was aspirated and each well was washed twice 
with 200µL of MQ water. We first added 25µL of SPA beads to each well, and then we added 
25µL of either control protein or alpha-synuclein protein. 50µL of oleic acid mixture at different 
concentrations were added to each well as the last component. The plate was sealed with 
adhesive plastic film and incubated at 37°C for 2 hours. The plate was cooled to room 
temperature for 10 minutes before it was read in the MicroBeta scintillation counter 
(Perkinelmer).  
We plotted count per minutes (cpm) detected at the different concentrations of oleic acid. Bmax, 
Kd, and hill constant were determined using nonlinear regression by fitting the data to a one-site 
binding model with hill slope: 
(y= Bmax*X
h
/Kd
h
+X
h
).  
Bmax = the concentration of oleic acid at which the binding sites on the receptors are 100% 
occupied. 
 Kd = the concentration of oleic acid at which half of the binding sites on the receptors are 
occupied.  
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Hill constant = the degree of co-operativity 
 
Dynamic Light Scattering (DLS) 
We determined critical micelle concentration (CMC) of oleic acid using Dynamic light scattering. 
Various concentrations of oleic acid were prepared by dissolving oleic acid in 30mM Tris-HCl 
pH7.4 buffer. The intensity of scattered light at each concentration was measured at 25°C using 
Nano ZS (Malvern Instrument, UK) with a measurement angle of 173°. 
Transfection in HEK293FT cells 
HEK293 cells were maintained in complete DMEM media (DMEM, 10% FBS, L-Glutamine and 
Penicillin/Streptomycin) in T-75 flasks. Cells in the flask were briefly washed with 5mL of PBS 
and dislodged with 1mL of Trypsin. The action of trypsin was stopped by adding 4mL of 
complete DMEM media (10% FBS, L-glutamine, NO antibiotics) into the flask. The cells were 
resuspended thoroughly in order to obtain a single-cell suspension and were transferred into a 
new 50mL Falcon tube (ALL tube). To prepare the cell sample for counting (COUNT tube), 
0.5mL of cell suspension was added into a new 50mL Falcon tube containing 4.5mL complete 
DMEM media (10%FBS, L-glutamine, NO antibiotics). Cell numbers were determined by 
counting cells using a hemocytometer. Cells were transfected in 6-well plate. To enhance the 
adhesion of cells onto the wells, each well was coated with 500µL of 1xPoly-D-Lysine 
Hydrobromide (sigma #P1149) for 2 hours prior to the transfection. HEK293 cells were 
transfected with either pcDNA3.1 Vector maxi or WT/mutant alpha-synuclein using 
Lipofectamine2000. The cells were incubated in DNA/Lipofectamine mixture (state the amount 
of DNA, lipofectamine, and number of cells per well) overnight at 37°C. The morning after 
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transfection, the media was changed to complete DMEM media with 10% FBS (DMEM, 
10%FBS, L-glutamine, Penicillin/Streptomycin).  
14
C Oleic acid pulse-labeling 
HEK 293 cells were maintained in complete DMEM media with 10% FBS (DMEM, 10%FBS, 
L-glutamine, Penicillin/Streptomycin). 2 hours prior to the pulse-labeling, the media was 
changed to the complete media with 2% dialyzed FBS (DMEM, 2% Dialyzed FBS, L-glutamine 
and Penicillin/Streptomycin). The pulse-solution containing 1mM fatty-acid free BSA, 
14
C-oleic 
acid and TBS (10mM Tris and 150mM NaCl) was prepared fresh and incubated at 37°C for 30 
minutes before pulsing the cells. To pulse-label the cells, 1mL of media was removed and 10µL 
of pulse-solution was added to each well. The plate was incubated at 37°C for 15 minutes.  
 Cell harvesting and extraction 
Immediately following the 15 minutes pulse-labeling, the cells were harvested in ice-cold 1xPBS. 
The cells were removed from each well and transferred into respective 1.5mL Eppendorf tubes. 
Cells were collected by centrifugation at 5000xg for 1minute at 4°C. The supernatant was gently 
removed from each tube and remaining PBS was removed by additional centrifugation at 5000xg 
for 30 second at 4°C. The cells were resuspended gently in 50µL ice-cold 1xPBS. 5µL of 
resuspended cells were transferred to a new 1.5mL Eppendorf tube and saved for BCA and 
ELISA assay. The remaining 45µL of resuspended cells was processed for extraction. To extract 
lipid from the cells, we used chloroform/methanol/water extraction procedure (Bligh and Dyer, 
1959). Briefly, 3.3 volumes (148.5µL) of 1:2 chloroform/methanol, 1.1 volume (49.5µL) of 
chloroform and 1 volume (45µL) of MQ water was added to each tube containing 45µL of 
resuspended cells in order. The tubes were vortexed after each addition. Following centrifugation 
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at 2000rpm at 25°C for 5minutes, separation into two phases (top aqueous and bottom organic 
phase) was observed. Both aqueous and organic phases were carefully removed and transferred 
into respective 1.5mL Eppendorf tubes. The bottom organic phase was used for TLC analysis.   
Thin Layer Chromatography (TLC) 
To separate each species in the extracted organic phase, 10μL of cell suspension from each 
sample plus four lipid standards (
14
C-PC, 
14
C-LPC, 
14
C-acyl-CoA and 
14
C-Oleic acid) were 
applied onto a silica gel coated glass plate. The TLC plate was developed in the 
Chloroform/methanol/water (65/25/4) system and visualized using a FLA-7000 phosphoimager 
(Fuji). The radioactive intensity of each spot was determined using Multigauge software (Fuji).  
Micro BCA Protein Assay 
5μL of resuspended cell extract were dissolved in 45μL of TBS (25mM Tris-HCl pH8 and 
150mM NaCl) buffer+1%Triton X and sonicated in a water bath for 1 minute. We used a BCA 
assay Kit (Thermo scientific) to quantify the total concentration of protein in each sample.   
Sandwich Enzyme linked Immunosorbent assay (ELISA) 
We used sandwich ELISA to detect the level of alpha-synuclein expression in each sample. Each 
well of the microtiter plate was coated with 50µL of carbonate coating buffer containing capture 
antibody (1µg/mL Asyn-211) and incubated overnight at 4°C. The following day, each well was 
washed 5 times with 1xPBS-tween 20 (150µL) and patted on a paper towel to remove the 
residual coating mixture. Protein-binding sites in each coated well were blocked with 150µL of 
blocking buffer (2% BSA-PBS) and incubated for 2 hours at 37°C. During the incubation we 
prepared samples for the standard curve by dilution of each purified recombinant alpha-synuclein 
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protein in the sample buffer (300mM Tris-HCl pH8, 0.25% BSA, 1X aprotinin, 1x Leupeptin 
and 0.1% triton in PBS) to the final concentration of 0, 0.1, 0.3, 0.9, 2.7, 8.1, 24.3 and 
72.8ng/mL. The 1000-fold diluted unknown sample and samples for the standard curve were 
loaded to each respective well, and the plate was incubated overnight at room temperature. Next 
day, each well was incubated with the detection antibody (1µg/mL FL-140) and then secondary 
antibody (HRP-anti rabbit), followed by detection with TMB and measurement of absorbance at 
650 nm.  
 
Statistics  
We analyzed data using student-t test (two-tailed, unpaired). In all the experiments, P values less 
than 0.05 are considered to be statistically significant.  
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Results 
1.1 Alpha-synuclein cooperatively interacts with monomeric fatty acid. 
 
We determined the binding of alpha-synuclein to oleic acid using a scintillation proximity 
assay (SPA). Recombinant human WT alpha-synuclein protein was purified using previously 
established method (Bagchi et al., 2013). The purified recombinant protein migrates as a single 
peak with a relative molecular weight of 57 kD in size-exclusion chromatography under native 
conditions. Using static light scattering (SLS), we also found the size of the purified recombinant 
protein to be around 57±7.27 kDa, consistent with the previously reported size of monomeric 
protein. To determine the interaction of alpha-synuclein with oleic acid, purified his-tagged-
human WT-alpha-synuclein protein was incubated with a range of different concentrations of 
3
H-
labeled oleic acid in the presence of chelated copper PVT beads. Because 
3
H oleic acid may 
interact directly with SPA beads, nonspecific binding was determined in parallel reactions 
containing oleic acid and beads without recombinant alpha-synuclein.  We calculated the alpha-
synuclein dependent binding at each oleic acid concentration by subtracting the non-specific 
binding from the total binding. A saturation binding curve was generated by plotting the specific 
binding versus the oleic acid concentration (Figure 1). Interestingly, we observed a sigmoidal 
relationship between specific binding values and oleic acid concentration, indicating cooperative 
binding of alpha-synuclein to oleic acid. We analyzed the data by fitting the curve to the 
equation using non-linear regression and obtained Kd, Bmax and Hill coefficient values. We 
observed specific binding of alpha-synuclein to oleic acid with a Kd of 4.27 μM, a Bmax of 
2599.25 cpm and a Hill coefficient of 4.83. Notably, these binding values were consistent across 
multiple independent sets of experiment. Because the hill coefficient represents the degree of 
cooperativity and values of hill coefficient >1 indicate positive cooperativity, these results 
support cooperative binding of oleic acid to alpha-synuclein.  
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Figure 1. Alpha-synuclein cooperatively binds to oleic acid. The binding interaction of alpha-
synuclein with oleic acid was characterized using scintillation proximity assay (SPA) at a range 
of different oleic acid concentrations (0-8μM).  
 
Fatty acids are amphiphilic molecules that contain hydrophobic tails and hydrophilic 
heads, which can aggregate to form micelles, similar to other surfactants. The concentration 
above which fatty acids form micelles is defined as the critical micelle concentration (CMC). 
Because oleic acid can form micelles and because alpha-synuclein has been observed to interact 
with SDS micelles in vitro (Bisaglia et al., 2005; Ulmer et al., 2005), we investigated the 
properties of oleic acid over the range of concentrations used in the binding assay, to further 
understand the nature of the alpha-synuclein-oleic acid complex. To determine whether the 
observed binding interaction was mediated by the binding of alpha-synuclein to monomeric oleic 
acid or to oleic acid micelles, we evaluated the CMC of oleic acid using Dynamic Light 
Scattering (DLS). Based on the principle that micelles can be detected by a change in light 
scattering properties relative to monomeric oleic acid (Davis et al., 2011), we measured light 
scattering intensity over a range of different concentrations of oleic acid. The estimated CMC of 
oleic acid in our assay was 30 μM (Figure 2). This result indicates that at the concentrations 
(<10µM) examined in the SPA assay, oleic acid molecules are in a monomeric state. Thus, the 
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binding observed in the SPA assay represents the interaction between alpha-synuclein and 
monomeric oleic acid molecules rather than micelles.  
 
 
Figure 2. Determination of critical micelle concentration (CMC) of oleic acid. The size of 
oleic acid was measured using dynamic light scattering (DLS) across different oleic acid 
concentrations (0-200μM). No significant light scattering was detected below 30μM, however, a 
linear increase in light scattering was observed beyond 30μM (Figure 2a). A line was plotted 
using the four oleic acid concentrations (50, 100, 150 and 200μM) at which changes in light 
scattering were observed (Figure 2b). CMC of oleic acid was estimated by finding the x-
intercept of the line. Consistent results were obtained across multiple independent experiments.   
 
 
Because we can mathematically calculate the mass of oleic acid at the concentration 
where all the binding sites on alpha-synuclein were occupied (Bmax), we estimated the mass ratio 
of alpha-synuclein and oleic acid in the complex. A critical factor in this calculation is the 
determination of counting efficiency needed to determine disintegrations per minute (dpm) from 
counts per minute (cpm). Due to the decay energy of the isotope, the counting efficiency of 
3
H 
using scintillation fluid is 42%. The counting efficiency of PVT-SPA beads has been estimated 
at 10% based on data in Dr. Kotzbauer’s lab comparing SPA to filter binding assays for 3H-
labeled ligands that bind to alpha-synuclein fibrils (Liu, J., Dhavale, D. and Kotzbauer, P., 
unpublished). Therefore, we estimated the overall counting efficiency of the assay to be 5%. The 
average Bmax value from multiple experiments was 2599.25 cpm, Using our estimated counting 
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efficiency (= cpm/dpm) of 5%, we obtained the average Bmax value of 51985 dpm. The average 
Bmax value (in dpm) was further converted to millimoles by first converting dpm to Curie (since 
1Ci = 2.22x10
12
, 51985 dpm / (2.22x10
12
dmp/Ci) =2.34x10
-8
 Ci), and specific activity 
(60Ci/mmole for 3H oleic acid 2.34x10
-8
 Ci / (60Ci/mmole) = 3.90x10-10 mmole) was used for 
conversion to mmoles. Because 
3
H-labeled oleic acid was diluted 100 fold with unlabeled oleic 
acid in the assay, we multiplied the value by 100 and found an average of 39 pmole oleic acid at 
Bmax. Given that each reaction contains 28 pmole of WT alpha-synuclein, this represents an 
approximately 1:1 mole ratio of oleic acid binding to alpha-synuclein in the SPA assay.  
 
 
1.2 Alpha-synuclein point mutants influence the binding of the protein to oleic acids.  
Since several lines of evidence from in vitro studies suggest that the N-terminus of alpha-
synuclein mediates binding to phospholipid vesicles and SDS micelles (Chandra et al., 2003; 
Davidson et al., 1998; de Laureto et al., 2006; Eliezer et al., 2001; Ulmer et al., 2005; Varkey et 
al., 2013), we asked if the binding of alpha-synuclein to oleic acid is also mediated by the N-
terminus of the protein. To address this question, we produced recombinant alpha-synuclein 
protein containing familial PD-associated missense mutations that are all located in the N-
terminus of the protein, and tested their ability to interact with oleic acid in the SPA assay. 
Briefly, each point mutation was created using site-directed mutagenesis. Recombinant alpha-
synuclein protein containing each mutation was purified as previously described. 0.28µM of 
each purified recombinant protein was incubated with his-tagged PVT SPA beads and 
3
H-labeled 
oleic acid at a range of different concentrations for 2 hours at 37°C. The curve was generated for 
each mutant by plotting the specific binding versus the range of different concentrations of oleic 
acid. Interestingly, we observed either little or no specific binding across the oleic acid 
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concentrations tested in the assay for both A30P and E46K mutants (Figure 3b-c), suggesting 
that both A30P and E46K mutations disrupt the binding of alpha-synuclein to oleic acid. In 
contrast, we observed sigmoidal relationships for A53T, H50Q and G51D mutants, indicating 
cooperative binding of each protein to oleic acid that is very similar to WT protein (Figure 3d-f). 
To determine Kd, Bmax and Hill coefficient values for each mutant, we analyzed the data with 
non-linear regression. We found Kd values of 5.47μM±0.60, 4.35 μM±0.33, 6.19 μM±1.12; Bmax 
values of 2409 cpm±488.4, 1553 cpm±94.0, 2619 cpm±941.9; and values of hill coefficient 
5.59±2.12, 15.18±7.42, 5.02±2.31; for A53T, G51D and H50Q mutants, respectively. The 
binding values of these three mutants are similar to the values of WT-alpha-synuclein (Kd = 
4.77μM±0.30, Bmax = 2181cpm±198.5 and hill coefficient = 4.78±1.01), suggesting that 
mutations at codon 50, 51 and 53 do not affect the binding interaction of the protein with oleic 
acid. Together, these results indicate that binding of alpha-synuclein to oleic acid is also 
mediated by the N-terminus of the protein. Specifically, codon 30 and 46 of N-terminus are 
required for alpha-synuclein-oleic acid interaction, as evidenced by the absence of binding 
observed in both A30P and E46K mutants.  
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Figure 3. Alpha-synuclein mutations affect oleic acid binding. Oleic acid binding interactions 
with human WT (Figure 3a), A30P (Figure 3b), E46K (Figure 3c), A53T (Figure 3d), G51D 
(Figure 3e) and H50Q (Figure 3d) alpha-synuclein were characterized using scintillation 
proximity assay (SPA). For both A30P and E46K alpha-synuclein proteins, no significant 
binding was observed over the range of oleic acid concentrations tested in the assay (Figure 3b-
c). The oleic acid binding observed for A53T, G51D and H50Q alpha-synuclein proteins were 
similar to that of WT alpha-synuclein (Figure 3a and b-f). Similar Bmax and Kd values were 
observed across multiple independent experiments for each protein.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
1.3 Wild type (WT) human alpha-synuclein enhances incorporation of free fatty acid into 
phospholipids in HEK293FT cells.  
 
Although Murphy et al did not observe binding of alpha-synuclein to oleic acid using 
titration microcalorimetry (Golovko et al., 2005), they observed reduction of fatty acid uptake 
and incorporation into phospholipid in alpha-synuclein-KO mice (Golovko et al., 2005; Golovko 
et al., 2007).  Notably, they also reported that alpha-synuclein affects fatty acid metabolism 
through modulation of acyl-CoA synthetases (ACS) enzymatic activity (Golovko et al., 2006). 
Thus, it is likely that overexpression of alpha-synuclein may promote ACS enzymatic activity 
and fatty acid incorporation rate into phospholipids.  
To begin to address this idea, previous studies in Dr. Kotzbauer’s lab explored whether 
alpha-synuclein modulates the activity of ACS enzymes in vitro. An in vitro enzymatic assay 
was utilized to evaluate the catalytic activity of two isoforms of ACS enzyme (ACSL3 and 
ACSL6) in a range of different concentrations of recombinant human WT alpha-synuclein 
protein.  Interestingly, they found that the catalytic activity of both isoforms increased with a 
sigmoidal dose response relationship to the concentration of alpha-synuclein protein (Figure 4a 
and b), indicating that the increased enzymatic activity was alpha-synuclein dependent. 
Importantly, A30P mutation abolishes the effect of WT alpha-synuclein on catalytic activity of 
the enzymes (Figure 4c), whereas the A53T mutation had no significant effect (Figure 4c).  
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Figure 4. Over-expression of human WT, but not A30P, alpha-synuclein increases catalytic 
activity of Acyl-CoA synthetases (ACS) enzymes. (Unpublished data from Dr. Kotzbauer lab) 
The effect of alpha-synuclein on the catalytic activity of two isoforms of ACS enzyme: ACSL3 
(Figure 4b and c) and ACSL6 (Figure 4a) were measured in an in vitro enzymatic assay. The 
catalytic rates of ACSL6 (Figure 4a) and ACSL3 (Figure 4b) were increased in an alpha-
synuclein dose dependent manner. A53T alpha-synuclein increased ACSL3 activity similar to 
WT alpha-synuclein, whereas A30P alpha-synuclein did not increase ACSL3 activity (Figure 
4c).   
 
Based on our finding that the A30P mutation disrupts the binding of alpha-synuclein to 
oleic acid, it is possible that the A30P mutation does not promote catalytic activity of ACS 
enzyme due to the absence of oleic acid binding. To determine the effect of WT and A30P alpha-
synuclein on ACS catalytic activity in vivo, we examined fatty acid incorporation rates in 
HEK293 cells transfected with alpha-synuclein expression plasmids. Briefly, either human-WT 
or human-A30P alpha-synuclein was over-expressed in HEK293FT cells using lipofectamine 
mediated transfection. 
14
C-labeled oleic acid was added to the cell media and incubated with the 
cells at 37°C for 15 minutes to allow the cells to metabolize the fatty acid. We then harvested 
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cells, extracted lipids, and separated individual lipid classes using thin layer chromatography 
(TLC). To determine the rate of oleic acid incorporation, we compared the amount of 
14
C-labeled 
phosphatidylcholine (PC) in cells over-expressing human WT alpha-synuclein and cells over-
expressing human A30P alpha-synuclein to control cells over-expressing no alpha-synuclein. 
Notably, we found that over-expressing human WT alpha-syuclein in the cells increased oleic 
acid incorporation into PC by approximately 20% (p<0.02 from three independent sets of 
experiment) (Figure 5a). In contrast, overexpressing human-A30P alpha-synuclein in the cells 
had no effect on the oleic acid incorporation rate (Figure 5b), supporting the idea that oleic acid 
binding and ACS enzymatic activity mediate the effect of alpha-synuclein on the fatty 
incorporation rate. 
 
 
Figure 5. Over-expression of human WT, but not A30P, alpha-synuclein increases oleic 
acid incorporation into phosphatidylcholine (PC) in HEK293FT cells. Compared to the 
control group (vector), HEK293FT cells over-expressing human WT alpha-synuclein exhibited 
an average of 20% increase in the rate of oleic acid incorporation into PC (Figure 5a). Oleic acid 
incorporation rate into PC was similar between vector and HEK293FT cells over-expressing 
A30P alpha-synuclein (Figure 5b). The rate of oleic acid incorporation into PC was presented as 
the % difference of control group (vector).  
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Because the number of cells and the alpha-synuclein expression level in each sample can 
affect the resulting amount of 
14
C-labeled PC, we estimated cell numbers and alpha-synuclein 
expression level using BCA and ELISA, respectively. We observed no difference in cell 
numbers (Figure 6a-b) and expression level of alpha-synuclein between WT and A30P groups 
(Figure 6c), further indicating that the increase in oleic acid incorporation is mediated by the 
binding and enzymatic activity.  
 
 
Figure 6. Cell numbers and alpha-synuclein expression levels were similar between 
HEK293 cells overexpressing Wild-type (WT) or A30P alpha-synuclein. The number of 
HEK293FT cells overexpressing human WT (Figure 6a) and A30P (Figure 6b) alpha-synuclein 
were estimated using BCA assay. Cell numbers in each group were similar to vector controls. 
Protein expression level of alpha-synuclein was determined using ELISA (Figure 6c). 
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Discussion 
 
In this study, we demonstrated using a scintillation proximity assay (SPA) that alpha-
synuclein cooperatively binds monomeric oleic acid with a Kd of 5 μM. Amino acid residues 30 
and 46 in the N-terminus of alpha-synuclein protein are required for oleic acid binding, as 
evidenced by the observation that both A30P and E46K mutations disrupt binding. We also 
demonstrated that alpha-synuclein increases the catalytic rate of Acyl-CoA synthetase (ACS) 
enzymes in vitro, and increases the rate of oleic acid incorporation into phosphatidylcholine in 
transfected HEK293FT cells. The disruptive effect of the A30P mutation on both fatty acid 
binding and enhanced FA incorporation rate indicates that alpha-synuclein promotes conversion 
of fatty acids to acyl CoAs by enhanced delivery of fatty acids to acyl CoA synthetase enzymes. 
Thus, our results support the hypothesis that alpha-synuclein controls a critical step needed to 
utilize fatty acids in multiple metabolic pathways. 
SPA is a novel assay to characterize the binding of alpha-synuclein to oleic acid 
We are the first to utilize SPA to characterize the binding of alpha-synuclein to fatty acid. 
Our results indicate that SPA is a valuable approach to characterize the interaction of alpha-
synuclein with oleic acid. Because SPA does not require the separation of bound from unbound 
ligand, the possibility of losing bound complex due to dissociation or inefficient capture on 
filters is reduced. Importantly, the binding we observe using SPA is consistent with previous 
studies (Karube et al., 2008; Sharon et al., 2001), confirming a direct interaction between alpha-
synuclein and oleic acid. The interaction of alpha-synuclein with oleic acid was not observed in 
study using titration microcalorimetry (Golovko et al., 2005), possibly because it lacked the 
sensitivity to detect an interaction based on thermodynamic measurements. Our results extend 
those of Sharon et al by demonstrating cooperativity in binding, in part because we were able to 
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detect the specific binding at lower concentration of alpha-synuclein (<0.28µM). However, our 
SPA requires further determination of counting efficiency in order to further increase the 
accuracy of Bmax calculations. Specifically, the efficiency of his-tagged alpha-synuclein capture 
by PVT-SPA beads and the efficiency with which beads capture emissions from 
3
H-oleic acid 
require further characterization.  
 
Characterization of the nature of alpha-synuclein-oleic acid complex 
Determination of the critical micelle concentration (CMC) of oleic acid revealed that the 
binding we observed in SPA represents the interaction of alpha-synuclein with monomeric oleic 
acid. There are two important reasons why we determined CMC of oleic acid. First, although the 
CMC of oleic acid has been estimated to be around 6μM (Davis et al., 2011), the CMC can 
change depending on the experimental conditions (pH, ionic strength or temperature). Second, 
fatty acid, as a surfactant, aggregates to form micelles with different sizes and shapes, which 
could exert different effects on its binding partner (Walde, 2006). Therefore, we specifically 
determined CMC of oleic acid under the same experimental condition where the binding 
interaction was observed. Since we found that the oleic acid concentrations we used in our 
binding assay were lower than the estimated CMC of oleic acid (~30uM) in our system, we 
concluded that the binding we observed was between alpha-synuclein and monomeric oleic acid. 
Our finding of the interaction between alpha-synuclein and monomeric oleic acid has a 
physiological significance in brain where the concentration of oleic acid in CSF is approximately 
3.6μM (Schmid et al., 2012).  
 
Our observation of an interaction between alpha-synuclein and monomeric oleic acid 
could explain the observed effect of alpha-synuclein on fatty acid micelle formation in vitro 
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(Broersen et al., 2006; De Franceschi et al., 2009) . Since CMC is determined by solubility of 
monomeric fatty acid, the reduction in free fatty acid monomer concentration by formation of 
alpha-synuclein-fatty acid complexes is likely to increase CMC. Because the effect of alpha-
synuclein on CMC of oleic acid has not been determined, we can further determine the ability of 
alpha-synuclein to increase CMC of oleic acid. It is also of interest to determine the interaction 
of alpha-synuclein with other fatty acid species. It has been previously reported that alpha-
synuclein affects micellar behavior of polyunsaturated fatty acids (AA and DHA) but not 
saturated fatty acids (arachidic and palmitic acids) (Broersen et al., 2006). Brain palmitate 
metabolism was decreased in the absence of alpha-synuclein, however, the binding of alpha-
synuclein to palmitic acid was not detected using titration microcalorimetry (Golovko et al., 
2005). Therefore, we could further characterize the binding of alpha-synuclein to palmitic acids 
(saturated fatty acid) and DHA (polyunsaturated fatty acid) using SPA. DHA plays important 
roles in brain function. Polyunsaturated fatty acids (PUFAs) can affect membrane properties and 
functions when incorporated into phospholipids (Hagve et al., 1998; Hulbert, 2008), PUFAs also 
have signaling roles (Bazan et al., 2011; Grintal et al., 2009). One study suggested high binding 
affinity of alpha-synuclein toward PUFAs (DHA>AA) using a competition assay in which the 
radiolabeled oleic acid binding was measured in the presence of unlabeled PUFA (Sharon et al., 
2001). Direct measurements of binding interactions using 
3
H-labeled PUFAs would provide 
further information on the binding affinities for different fatty acid species. Together, both 
binding results and the effect of alpha-synuclein on micellar behavior of fatty acids indicate 
direct interactions of alpha-synuclein with several different free fatty acid species.  
Importantly, we were also able to relate alpha-synuclein-fatty acid interactions to the 
effect of human WT alpha-synuclein on fatty acid metabolism in cells. Our cell culture studies 
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revealed that human WT, but not A30P, alpha-synuclein over-expression enhanced the rate of 
oleic acid incorporation into phospholipid by approximately 20%. Together with the observation 
that the A30P mutation disrupted oleic acid binding, the inability of A30P alpha-synuclein to 
promote oleic acid incorporation into phospholipid supports the hypothesis that the regulatory 
role of alpha-synuclein in fatty acid metabolism is mediated by the direct binding of alpha-
synuclein to fatty acids. This idea is further supported by our observations in the in vitro 
enzymatic assay that recombinant human WT-alpha-synuclein increases the catalytic activity of 
two ACS enzymes, ACSL3 and ACSL6, while recombinant A30P alpha-synuclein has no effect 
(unpublished data in Kotzbauer lab). Furthermore, the effect of alpha-synuclein in fatty acid 
metabolism observed in our alpha-synuclein over-expression studies are consistent with previous 
findings reported in mice with a targeted alpha-synuclein gene mutation, in which fatty acid 
incorporation into phospholipid was found to be reduced through reduced enzymatic activity of 
acyl-CoA synthetases (Golovko et al., 2005; Golovko et al., 2006; Golovko et al., 2007).  
The effect of fatty acid binding on the structural conformation of alpha-synuclein 
The N-terminus of alpha-synuclein plays an important role in its interactions with 
phospholipid vesicles and SDS micelles and adopts alpha-helical structure upon the bindings 
(Chandra et al., 2003; Davidson et al., 1998; de Laureto et al., 2006; Eliezer et al., 2001; Perrin et 
al., 2000; Ulmer et al., 2005; Varkey et al., 2013). While studies report alpha-helical structural 
change of the protein in the presence of fatty acid (Broersen et al., 2006; Perrin et al., 2001), 
whether monomeric fatty acids also induce the conformational changes in the protein is unclear. 
Although further studies are needed to determine the changes in alpha-helical contents, our 
binding studies using mutagenesis demonstrate that the amino acids at position 30 and 46 in the 
N-terminus of protein are required for fatty acid binding. Here, we proposed two possible 
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hypotheses of the effect of fatty acid binding on the alpha-synuclein structure based on our 
results. First, since monomeric fatty acid is far smaller in size relative to phospholipid vesicles 
and micelles, it is possible that fatty acid binding may not be associated with a conformational 
change of the protein from unfolded to alpha-helical structure.  
Alternatively, similar to binding interactions with phospholipid vesicles (Davidson et al., 
1998; Eliezer et al., 2001) and SDS micelles (de Laureto et al., 2006; Ulmer et al., 2005), alpha-
synuclein may also adopt alpha-helical structure upon interaction with monomeric fatty acid. The 
proline substitution in the A30P mutant disrupts alpha-helix formation (Bussell and Eliezer, 
2001) and disrupts binding interactions with vesicles (Bussell and Eliezer, 2004; Perrin et al., 
2000). The E46K mutation also causes local disruption of alpha-helical structure but retains its 
ability to interact with phospholipid. Based on the previous reports that both A30P and E46K 
mutations reduce the alpha-helical content and our observations in this study that both mutants 
disrupted oleic acid binding, we propose that conformational transition to alpha-helical structure 
may also be important for oleic acid binding.  However, the effect of the E46K mutation on 
interactions with fatty acids but not phospholipid vesicles may indicate distinct structural 
requirements for fatty acid binding. Further determination of alpha-helical content upon oleic 
acid binding using circular dichroism (CD) could provide a better understanding of the role of 
alpha-synuclein structural conformation in the interaction with free fatty acids.  
 
Possible roles of fatty acid binding in alpha-synuclein fibril formation 
Natively unfolded alpha-synuclein (Weinreb et al., 1996) adopts alpha-helical structure 
upon the interaction with phospholipid vesicles (Chandra et al., 2003; Davidson et al., 1998; 
Ulmer et al., 2005), but the aggregated form of alpha-synuclein found in neurodegenerative 
disorders is defined by beta-sheet structure. Although the normal function of alpha-synuclein is 
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not understood, structural changes related to its normal function may affect protein mis-folding 
and aggregation. For example, a previous study reported that the conformational transition from 
unfolded to alpha-helical structure upon the association of alpha-synuclein with membrane 
phospholipid inhibits fibril formation (Zhu and Fink, 2003). The effect of monomeric fatty acid 
binding on alpha-synuclein fibril formation has not been studied. While the A30P mutation is 
implicated in PD pathogenesis, A30P alpha-synuclein forms fibrils slowly relative to WT alpha-
synuclein in vitro. The different observations between in vitro and in vivo experimental systems 
could be explained by an effect of fatty acids. In the absence of fatty acids in vitro, the rate of 
fibril formation depends primarily on the intrinsic ability of the protein to adopt a conformational 
change and self-associate. On the other hand, when fatty acids are present in vivo, disruption of 
fatty acid binding due to the proline substitution in part could explain the accelerated alpha-
synuclein pathology in A30P mutant. Alpha-helical structure stabilized by fatty acid binding 
could reduce the probability of the protein to adopt β-sheet structure, thereby hindering protein 
aggregation. Furthermore, even in the absence of an alpha-helical shift, the formation of alpha-
synuclein-oleic acid complex could hinder protein aggregation by reducing the ability of free 
alpha-synuclein monomers to self –associate, either in the nucleation or extension phases of fibril 
formation.  
 
It is also possible that fibril accumulation is regulated by multiple other mechanisms. 
Increased intercellular levels of alpha-synuclein monomer may promote fibril formation, as 
suggested by alpha-synuclein gene duplication and triplication mutations linked to rare familiar 
PD (Singleton et al., 2003). Multiplication of the alpha-synuclein gene is predicted to increase 
protein production; thereby increasing the concentration of alpha-synuclein monomers in 
neurons. In addition to production, clearance of alpha-synuclein can also regulate the level of 
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alpha-synuclein monomers. It has been shown that alpha-synuclein protein is degraded by both 
the ubiquitin-proteasome pathways as well as lysosome pathways (Lee et al., 2004; Mak et al., 
2010) and therefore alteration in alpha-synuclein clearance may also contribute to fibril 
formation.  
 
Potential role of fatty acid metabolism in the pathogenesis of PD  
Our findings in this study support the regulatory role of alpha-synuclein in fatty acid 
metabolism. Our findings further suggest that altered fatty acid metabolism may also be 
implicated in PD pathogenesis. In fact, a population-based Rotterdam study looked at the 
relationship between dietary intake of fatty acids and the risk of developing PD. The study 
reported that increased dietary intake of total fat, monounsaturated fatty acids and 
polyunsaturated fatty acids lowered the risk of developing PD (de Lau et al., 2005), suggesting 
that altered fatty acid metabolism could contribute to the pathogenesis of PD. Furthermore, 
altered fatty acid metabolism is also associated with a genetic mutation that increases the risk of 
developing PD. The glucocerebrosidase (GBA) gene encodes the enzyme β-glucocerebrosidase, 
which hydrolyzes glucosylceramide to produce ceramide. While homozygous mutation of GBA 
gene causes an autosomal recessive lysosomal storage disorder called Gaucher’s disease, 
heterozygous GBA mutations are associated with an increased risk of PD (Mitsui et al., 2009; 
Sidransky and Lopez, 2012). What causes the increased susceptibility to PD in patients with 
heterozygous GBA mutations remains unclear.  One study compared fatty acid levels in CSF of 
GBA-PD patients with both idiopathic PD and healthy controls, and found significantly lower 
fatty acid levels in CSF of GBA-PD patients (Schmid et al., 2012), further supporting the 
correlation of altered fatty acid metabolism with increased risk of PD. Hydrolysis of 
glucosylceramide is an important intermediate step in sphingolipid metabolism in which 
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sphingolipid is broken down to produce free fatty acids and sphingosine. Although 
glucosylceramidase is not directly involved in the hydrolysis reaction that produces free fatty 
acids, it certainly could be the rate limiting step in the conversion of glucosylceramide to fatty 
acids. Therefore, reduced enzymatic activity of glucosylceramidase caused by GBA mutations 
could change the rate of free fatty acid production.   
 
The potential involvement of fatty acid metabolism in the pathogenesis of PD raises the 
importance of studying dietary fatty acid intake and fatty acid levels in CSF in PD patients. 
Future studies that relate changes in fatty acid levels and changes in alpha-synuclein levels in 
CSF could further confirm the interaction of alpha-synuclein and fatty acids in brain and the 
implication of alpha-synuclein-fatty acid interaction in the pathogenesis of PD. 
 
Implication of alpha-synuclein-fatty acid interaction in pla2g6-KO mice 
The underlying molecular mechanism of how PLA2G6 mutation causes 
neurodegeneration remains to be defined. Since the conversion of free fatty acid to acyl-CoA is 
an essential step that regulates downstream metabolic processes, deficiency in free fatty acid 
production caused by PLA2G6 mutations is considered as one of the possible mechanisms 
underlying neurodegeneration. Our results support the role of alpha-synuclein in the fatty acid 
activation step. Specifically, alpha-synuclein directly binds to free fatty acids and increases the 
enzymatic activity of acyl-CoA synthetase, resulting in increased acyl-CoA production. PLA2G6 
mutations cause the disruption of Pla2g6 enzyme to produce free fatty acid through the 
hydrolysis of phospholipid. Although free fatty acids are available from other sources, such as 
dietary intake and breakdown by other lipases, the free fatty acid pools that are available for 
conversion to acyl-CoA are likely to be significantly reduced in INAD. Based on our findings of 
 79 
 
the role of alpha-synuclein in the fatty acid activation step, we hypothesize that the alpha-
synuclein mediated increase in acyl-CoA production could compensate for the deficiency in free 
fatty acid production in Pla2g6-KO mice. Therefore, the ability of alpha-synuclein to increase 
acyl-CoA production could explain why over-expression of human WT alpha-synuclein 
improves the neurologic impairment of Pla2g6-KO mice.   
 
Potential role of tetrameric structure in the interaction of alpha-synuclein with fatty acids 
The observation of cooperativity in binding is of special interest in the current debate 
about the structure of native alpha-synuclein. Although it remains controversial, studies have 
indicated that native alpha-synuclein exists as a tetramer with alpha-helical structure rather than 
a natively unfolded monomer (Bartels et al., 2011; Wang et al., 2011). In this study, to 
understand the cooperativity and the nature of alpha-synuclein-oleic acid complex observed in 
SPA, we estimated the mole ratio of alpha-synuclein to oleic acid to be approximately 1:1. 
Cooperative binding indicates that binding of a ligand to one binding site on a receptor increases 
the binding affinity of the ligand to other sites on the same receptor. If the 1:1 ratio is correct, it 
indicates that alpha-synuclein must exist as a multimer in order to produce cooperative binding, 
and at least four alpha-synuclein monomers must be present in the complex in order to explain 
the hill coefficient of 4 observed in our assays. Alternatively it is possible that we underestimated 
the Bmax value for oleic acid in the assay, possible because we over-estimated the efficiency of 
dpm detection in the assay, in which case it is possible that 4 or more oleic acid molecules bind 
to a single alpha-synuclein monomer in a cooperative fashion. We estimated the molecular 
weight of recombinant alpha-synuclein to be 57kD using static light scattering (SLS) which is 
consistent with the size reported for both the disordered monomer as well as the alpha-helical 
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tetramer.   Further size measurements in the presence of fatty acid, perhaps in combination with 
circular dichroism studies to measure alpha-helical content, could help determine structural 
changes that occur when alpha-synuclein binds to fatty acids.   
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Future Directions 
 
In our study, we demonstrated the binding interaction of alpha-synuclein with oleic acid 
using SPA assay. Although oleic acid is a common monounsaturated fatty acid, it is only one 
type of many fatty acids that exist. Structurally different fatty acids (ex, saturated vs unsaturated) 
play different roles in lipid metabolism. Previous studies suggest that alpha-synuclein interacts 
with polyunsaturated fatty acid (ex. DHA, AA) but not with saturated fatty acids (ex. Palmitic 
acid) although affinities were not measured or compared (Broersen et al., 2006). To further 
understand the interaction of alpha-synuclein with fatty acids, we propose to evaluate the binding 
of alpha-synuclein to other fatty acids species using the same method we used for oleic acid. If 
the binding is observed, we can examine binding affinities (Kd value) of alpha-synuclein toward 
different fatty acids in our SPA assay. Since each fatty acid may be involved in different 
metabolic pathways, differences in binding affinity will be helpful to understand the potential 
role of alpha-synuclein in these particular metabolic pathways. 
Our results from in vitro and cell culture studies support the regulatory role of alpha-
synuclein in fatty acid metabolism by increasing acyl-CoA production. To further determine if 
alpha-synuclein increases Acyl-CoA levels in vivo, we propose to study the effect of alpha-
synuclein over-expression on fatty acid incorporation in mice. Using the in vivo kinetic method 
described by others (Golovko et al., 2006; Rapoport, 2001), we can measure the kinetics of brain 
oleic acid metabolism in WT alpha-synuclein transgenic mouse line (M7 syn) in which human 
WT alpha-synuclein is over-expressed in neurons (Giasson et al., 2002).  Based on the results in 
this study, we expect to detect a higher rate of oleic acid incorporation into phospholipids in M7 
syn transgenic mice, compared to wild-type mice. Such observations will further support our 
findings in this study. In addition, our results suggested that the fatty acid binding is required for 
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alpha-synuclein to regulate fatty acid metabolism. To further examine the effect of binding 
interaction on the ability of alpha-synuclein to promote acyl-CoA synthesis, we propose to 
compare the kinetics of brain oleic acid metabolism in wild-type mice to that in wild-type mice 
over-expressing either the A30P or E46K mutation.  
Based on the ability of alpha-synuclein to increase acyl-CoA production, we predicted 
that an alpha-synuclein-mediated increase in acyl-CoA synthesis compensates the deficiency in 
free fatty acid production caused by PLA2G6 mutation in Pla2g6-KO mice. To further test if our 
prediction underlies the protective effect of human WT alpha-synuclein over-expression on the 
motor performance observed in Pla2g6-KO mice, we propose to measure the kinetics of brain 
oleic acid metabolism in Pla2g6-KO/human WT alpha-syn transgenic (Pla2g6-/-syn+/+) mice 
and appropriate controls; Pla2g6-KO/human WT alpha-syn non-transgenic (Pla2g6-/-syn-/-), 
Pla2g6-WT/human WT alpha-syn transgenic (Pla2g6+/+syn+/-) and WT (Pla2g6+/+syn-/-) mice, 
using the same in vivo kinetic method described previously (Golovko et al., 2006; Rapoport, 
2001). If we detect a higher rate of oleic acid incorporation into phospholipid in Pla2g6-
KO/human WT alpha-syn transgenic (Pla2g6-/-syn+/+) mice compared to Pla2g6-KO/human 
WT alpha-syn non-transgenic (Pla2g6-/-syn-/-), this observation will confirm our prediction that 
the protective effect of alpha-synuclein on motor performance is mediated by increased acyl-
CoA synthesis which compensates for impaired free fatty acid production caused by PLA2G6 
mutations.  
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Currently, no cure is available for INAD. Based on our knowledge about the possible role 
of fatty acid metabolism in pathogenesis of the disease and findings in our current study, further 
studies can be proposed to test potential therapeutic approaches that target the fatty acid 
activation pathway in INAD.  For instance, if our hypothesis that an alpha-synuclein-mediated 
increase in acyl-CoA synthesis underlies the observed improvement in motor performance of 
Pla2g6-KO/human WT alpha-synuclein transgenic mice is confirmed, such observations will 
support acyl-CoA synthesis as a therapeutic target for treating INAD. While the ability of alpha-
synuclein to promote acyl-CoA production is supported by our studies and others (Golovko et al., 
2005; Golovko et al., 2006),   increasing the expression level of alpha-synuclein in INAD 
patients is impractical approach due to the self-aggregation property of the protein.  Instead, it is 
appropriate to target ACS enzymes. Therefore, identifying and developing drugs that increase the 
protein expression level of ACS enzymes or that increase enzymatic activity could increase acyl-
CoA production in INAD patients.  
Retinoid X receptor (RXR) is a ligand-dependent nuclear receptor transcription factor 
that can interact with other transcriptional activators (ex. liver X receptor and peroxisome 
proliferator-activated receptor) to increase the expression of enzymes that regulate cholesterol 
and fatty acid metabolism (Martin et al., 2000; Yoshikawa et al., 2001). Sterol response element 
binding protein (SREBP-1c) is a transcription regulator that binds to sterol regulatory elements 
of genes that encode enzymes for fatty acid synthesis; thereby up-regulation of SREBP-1c 
expression increases the expression level of fatty acid synthetases that produce acyl CoAs 
(Martin et al., 2000).  For example, Bexarotene, a FDA approved RXR agonist, increases ACSL3 
mRNA levels. Brain ACSL3 mRNA level was increased by 41% in mice treated with 
Bexarotene diet compared to mice with control diet (Bagchi and Kotzbauer, unpublished results). 
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Interestingly, one study also reported that nicotine increases mRNA and protein level of ACSL6 
in mouse brain (Chen et al., 2011). Further studies could test whether these approaches to 
increase brain acyl CoA levels reduce neurologic impairment in Pla2g6-KO mice. 
A better understanding of therapeutic targets is helpful for probing the molecular 
mechanisms of drug actions and for identifying features that guide new drug design. Therefore, a 
better understanding of brain ACS enzymes is helpful in developing approaches to increase 
activities of these enzymes. ACS enzymes play a critical role in fatty acid metabolism. Except 
for eicosanoid metabolism, esterification of free fatty acid by ACS enzymes to acyl-CoA is 
required for fatty acids to be utilized in downstream metabolic processes. In addition to their 
enzymatic functions to activate free fatty acids, they also regulate cellular uptake and channeling 
of fatty acids (Mashek et al., 2007). ACS enzymes are grouped into families depending on the 
acyl-chain lengths of free fatty acids to which they interact (Soupene and Kuypers, 2008). 
Isoforms in each ACS family differ in their substrate preferences and intracellular localization 
(Lewin et al., 2001; Mashek et al., 2007; Soupene and Kuypers, 2008), suggesting the activity of 
each enzyme to regulate fatty acid metabolism in a localization-dependent manner. Of the eleven 
enzymes from the three gene families; long-chain acyl-CoA synthetases (ACSLs), Bubblegum 
acyl-CoA synthetases (ACSBG) and Fatty acid transporter protein (FATPs), ACSL3, ACSL6, 
FATP4 and ACSBG1 are highly expressed in the brain (Chen et al., 2011; Golovko et al., 2006; 
Hall et al., 2005; Kee et al., 2003; Pei et al., 2003). However, the physiologic function and 
localization of each enzyme within the brain have not been completely characterized. Since the 
direct protein-protein interaction was not detected between alpha-synuclein and two isoforms 
(ACSL3 and ACSL6) of ACS enzymes using co-immunoprecipitation (data not shown), we 
hypothesized based on our results that alpha-synuclein binds to fatty acid and then delivers fatty 
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acid to the enzyme sites for increased fatty acid activation. Further studies that examine the 
localization patterns of ACS in neurons can test our hypothesis.  The observation of ACS 
enzymes in dendrites, axons and presynaptic terminals where alpha-synuclein and pla2g6 are 
localized will further support our hypothesis.  
The results of our binding studies also have potential implications in the pathogenesis of 
PD. We speculate that the interaction of alpha-synuclein with fatty acids could reduce the 
probability of the protein to self-aggregate, because of either the conformational changes to more 
stable structure or the reduction of free monomer concentration. Using an in vitro fibril 
formation assay, we can determine the effect of fatty acid on the rate of fibril formation for WT, 
A30P, and E46K alpha-synuclein protein. An observed reduction in the fibril formation rate for 
WT but not for A30P and E46K in the presence of fatty acid could support the notion that fatty 
acid binding affects self-aggregation. Cell-based assays and transgenic mice have been 
developed to study fibril formation by alpha-synuclein protein. To further study the relationship 
between fatty acids and fibril formation, we could add fatty acid to a cell-based aggregation 
assay and examine changes in the rate of fibril formation. We also could modulate the level of 
fatty acids in the diet for transgenic mice and evaluate corresponding changes in the 
accumulation of fibrillar alpha-synuclein.  
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